SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

Zebec Network (ZBCN) is generating intense community buzz as investors eye upcoming industry events and potential partnership announcements that could catalyze a shift in its market trajectory. While some participants urge caution regarding volatility and past performance, many are actively accumulating tokens, citing the project's real-world utility and long-term potential as key reasons for their bullish conviction.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is seeing a surge in investor interest and massive trading volume driven by a strong, momentum-fueled rally that has trapped short sellers and sparked intense community enthusiasm. The discussion centers on the company's progress in optical interposer technology and anticipated commercial partnerships, with many long-term shareholders viewing this price action as institutional validation.

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

Intellia Therapeutics is trending as investors await topline clinical data from its Phase 3 HAELO trial, with the stock seeing increased volatility and significant speculative interest due to high short interest. Market participants are actively debating the potential for a short squeeze alongside the company's progress in advancing its gene-editing platform toward potential commercialization.

APE fuels culture. Backed by the best club in the world and hundreds of thousands of holders worldwide, it’s the token for digital and IRL communities, builders, creators, collectors, gamers, and beyond.  APE is the native gas token of ApeChain and is available across multiple ecosystems including Ethereum, Arbitrum, Solana and HyperLiquid.z  ApeCoin's mission is is to supercharge its ecosystem by supporting high-quality builders &amp; reinforcing 3 core pillars: ApeChain, Bored Ape Yacht Club, and Otherside.

ApeCoin

ApeCoin is seeing a surge in community interest and trading volume, driven by speculation over a potential price breakout and ongoing buzz regarding its ecosystem and NFT-linked utility. While some investors are bullish on recent technical patterns and market sentiment, others remain cautious, debating whether the movement is a genuine recovery or a temporary liquidity trap.

X-Energy, Inc. operates as an energy company The firm focuses on modular nuclear reactors and fuel technology for clean energy generation. The company was founded by Kam Ghaffarian and Eben Mulder on 2009 and is headquartered in Rockville, MD.

X-Energy Inc. - Ordinary Shares- Class A

X-energy Inc

X-energy is capturing intense community interest during its market debut, driven by its status as an Amazon-backed nuclear startup focusing on small modular reactor technology to meet surging AI data center energy demand. Investors are actively debating the company's long-term potential versus valuation concerns, with many closely watching for price stabilization as the stock navigates the high-volatility environment typical of major new public listings.

Atomera, Inc. engages in the development, commercialization, and licensing of proprietary processes and technologies for the semiconductor industry. It developed Mears Silicon Technology, which increases performance and power efficiency in semiconductor transistors. The company was founded by Robert Mears on November 26, 2001 and is headquartered in Los Gatos, CA.

Atomera Inc

Atomera Inc. is seeing intense community discussion driven by speculation regarding potential commercial licensing deals with major semiconductor players for its Mears Silicon Technology, particularly following expanded collaborations and industry demand for next-generation transistor efficiency. While bulls point to technical validation and high-volume wafer runs as catalysts for a major re-rating, bears continue to cite the lack of sustained revenue and historical patterns of share price dilution.

Charter Communications, Inc. engages in providing broadband communications services. Its services include Spectrum TV, Spectrum Internet, and Spectrum Voice. It offers business-to-business Internet access, data networking, business telephone, video and music entertainment services, and wireless backhaul. Its advertising sales division, Spectrum Reach, offers local, regional, and national businesses the opportunity to advertise in individual and multiple service areas on cable television networks and advanced advertising platforms. The company was founded in 1993 and is headquartered in Stamford, CT.

Charter Communications Inc. - Ordinary Shares - Class A

Charter Communications is experiencing intense volatility and record trading volume following a significant post-earnings sell-off that has triggered widespread debate over the company's long-term viability against streaming and wireless competitors. While some investors are aggressively shorting the stock, others are aggressively buying the dip, viewing the aggressive share buyback potential and depressed valuation as an oversold opportunity.

Wolfspeed, Inc. is an innovator of wide bandgap semiconductors, focused on silicon carbide and gallium nitride (GaN) materials and devices for power and radiofrequency (RF) applications. Its product families include silicon carbide and GaN materials, power devices and RF devices, and its products are targeted for various applications such as electric vehicles, fast charging, 5G, renewable energy and storage, and aerospace and defense. The company was founded by Calvin H. Carter Jr., John W. Palmour, F. Neal Hunter, Eric Hunter, and John Edmond in 1987 and is headquartered in Durham, NC.

Wolfspeed Inc - Ordinary Shares (New)

Wolfspeed Inc

Wolfspeed is drawing significant investor attention following a major IRS tax refund that bolstered its cash position, strengthening its liquidity after exiting restructuring. The community is actively debating the company's long-term potential in the silicon carbide market, with heavy focus on its high short interest and speculative squeeze dynamics.

Comcast Corp. engages in the provision of video, Internet, and phone services. It operates through the following segments: Residential Connectivity and Platforms, Business Services Connectivity, Media, Studios, and Theme Parks. The Residential Connectivity and Platforms segment consists of residential broadband and wireless services and Sky-branded entertainment television networks and advertising. The Business Service Connectivity segment offers broadband, wireline voice and wireless services through small to medium customers and large enterprises through the HFC network. The Media segment consists of NBCUniversal’s television and streaming platforms, including national, regional, and international cable networks. The Studios segment focuses on NBCUniversal’s film and television studio production and distribution operations. The Theme Parks segment operates Universal theme parks in Orlando, Florida, Hollywood, California, Osaka, Japan, and Beijing, China. The company was founded by Ralph Roberts in 1963 and is headquartered in Philadelphia, PA.

Comcast Corp - Ordinary Shares - Class A

Comcast Corp

Comcast is trending as the market digests the company's decision to exit the bidding war for Warner Bros. Discovery, signaling a disciplined approach to capital allocation and a shift in focus back to internal growth strategies. Investors are also actively debating the upcoming Versant Media spin-off and the broader impact of this strategic pivot on long-term valuation.

Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of proprietary antibody therapeutics. Its platform includes common light chain-focused antibody discovery, human display for antibody tuning, stitchmabs, and highly modular and manufacturable bispecific candidates. The company was founded by Thomas J. Schuetz in 2014 and is headquartered in Boston, MA.

Compass Therapeutics Inc

Compass Therapeutics is generating significant investor buzz ahead of a highly anticipated topline data readout for its Phase 2/3 study of tovecimig in patients with biliary tract cancer. The community is focused on the potential for this binary event to validate the company's bispecific antibody platform, with traders closely monitoring call option activity and management commentary regarding survival endpoints.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Intellia Therapeutics (NASDAQ:NTLA) Trading Down 6.6%  - Should You Sell?

Intellia Therapeutics (NASDAQ:NTLA) Shares Down 6.6% - Should You Sell...

Sumitomo Mitsui Trust Group Inc. Has $19.71 Million Holdings in Intellia Therapeutics, Inc. $NTLA

Sumitomo Mitsui Trust Group Inc. decreased its position in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 6.9% in the 4th quarter, according to the company in its most recent...

Intellia Therapeutics (NASDAQ:NTLA) Stock Price Down 5.4%  - Should You Sell?

Intellia Therapeutics (NASDAQ:NTLA) Shares Down 5.4% - Should You Sell...

NTLA Stock Rises 20% in 3 Months: Here's What You Should Know

Intellia stock climbs nearly 20% in three months as pipeline progress, lifted FDA holds, and late-stage study updates boost investor optimism.

Take the Zacks Approach to Beat the Markets: LiveOne, Micron, Clorox in Focus

LVO, MU and CLX highlight how Zacks strategies and portfolio picks are delivering strong gains despite recent market volatility.

Hudson Bay Capital Management LP Sells 235,000 Shares of Intellia Therapeutics, Inc. $NTLA

Hudson Bay Capital Management LP lowered its stake in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 50.5% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned...

Take the Zacks Approach to Beat the Markets: Starbucks, Amgen, Allogene in Focus

ALLO, SBUX and AMGN highlight how Zacks strategies and portfolio picks are delivering strong gains despite recent market volatility.

Intellia Therapeutics (NASDAQ:NTLA) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Intellia Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday...

Intellia Therapeutics, Inc. (NASDAQ:NTLA) Given Average Recommendation of "Hold" by Brokerages

Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Get Free Report) have received an average recommendation of "Hold" from the twenty-one analysts that are presently covering the stock, Marketbeat...

ARK Investment Management LLC Trims Stake in Intellia Therapeutics, Inc. $NTLA

ARK Investment Management LLC lessened its position in Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 8.4% in the third quarter, according to the company in its most recent filing with...

Up 5%

Down 5%

Show me the results

Which direction is the next 5% move for the S&amp;P 500?

Stocktwits

Which direction is the next 5% move for the S&P 500?

Stocktwits Polls

Traders are closely watching the upcoming Phase 3 trial results for Hereditary Angioedema on April 27, 2026.

High short interest has speculators betting on a violent move upward to force forced covering among bears.

Investors are actively accumulating shares following volatile intraday drops they perceive as intentional manipulation.

NTLA
Intellia Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest NTLA News

NTLAIntellia Therapeutics Inc